Catalyst Pharmaceuticals (NASDAQ:CPRX) recently showcased significant growth within its rare disease portfolio, particularly for its lead product, Firdapse. During a discussion with Barclays life sciences analyst...
Entrada Therapeutics (NASDAQ: TRDA) recently presented its strategic vision for 2026 at the Guggenheim 2026 Emerging Outlook Biotech Summit, highlighting a series of anticipated clinical data...